Gypenoside LVI
Gypenoside LVI is an orally active dammarane-type triterpenoid compound found in Gynostemma pentaphyllum. Gypenoside LVI inhibits ERK and JNK phosphorylation, the NLRP3 inflammasome, and modulates M1 to M2 microglial polarization. Gypenoside LVI downregulates PCSK9 expression through a SREBP-independent pathway. Gypenoside LVI promotes cholesterol efflux via ABCG1 and SRB1, upregulates LXRα-mediated reverse cholesterol transport, and attenuates foam cell formation by reducing lipid accumulation and cholesterol uptake. Gypenoside LVI inhibits IL-6 and IL-1β secretion, reduces oxidative stress, neuroinflammation, microglial and astrocyte activation, and inhibits LPS-induced microglial proliferation. Gypenoside LVI can be used for research on atherosclerosis, hypercholesterolemia, depression, and non-small cell lung cancer.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- CAS. Nr.: 105214-48-0
- Formel: C53H90O23
- Molecular Weight:1095.28
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biologische Aktivität
Beschreibung
|
ERK |
JNK |
NLRP3 |
PCSK9 |
ABCG1 |
SRB1 |
LXRα |
IL-6 |
IL-1β |
In Vitro
Gypenoside LVI (GPLVI) (24 h) inhibits ox-LDL-induced foam cell formation in RAW264.7 cells[1].
Gypenoside LVI (100 μg/mL; 24 h) dose-dependently reduces TG content in ox-LDL-induced RAW264.7 macrophages[1].
Gypenoside LVI (100 μg/mL; 24 h) attenuated the elevated CE/TC ratio in ox-LDL-induced RAW264.7 macrophages[1].
Gypenoside LVI (25-100 μg/mL; 4 h) dose-dependently reduces the uptake of Dil-ox-LDL by RAW264.7 macrophages[1].
Gypenoside LVI (25-100 μg/mL; 24 h) enhances HDL-mediated cholesterol efflux at 50 μg/mL, whereas 25 and 100 μg/mL reduce cholesterol efflux in RAW264.7 macrophages[1].
Gypenoside LVI (25-100 μg/mL; 24 h) upregulated the mRNA expression of ABCG1, SRB1, and LXRα in ox-LDL-induced RAW264.7 macrophages[1].
Gypenoside LVI (25-100 μg/mL; 24 h) upregulates the protein expression of ABCG1, SRB1, and LXRα in RAW264.7 macrophages[1].
Gypenoside LVI (25-100 μg/mL; 24 h) inhibits ERK and JNK phosphorylation in ox-LDL-induced RAW264.7 macrophages[1].
Gypenoside LVI (25-100 μg/mL; 24 h) inhibits IL-6 and IL-1β production in ox-LDL-induced RAW264.7 macrophages, but does not reduce TNF-α production[1].
Gypenoside LVI (compound 2) (20-100 μM; 24 h) inhibited the viability of HepG2 cells[2].
Gypenoside LVI (5-20 μM; 24 h) inhibits PCSK9 secretion in LPDS-induced HepG2 cells[2].
Gypenoside LVI (5-20 μM; 24 h) reduces PCSK9 protein expression in HepG2 cells[2].
Gypenoside LVI (5-20 μM; 24 h) increases LDLR protein expression in HepG2 cells[2].
Gypenoside LVI (5-20 μM; 24 h) reduces Simvastatin (HY-17502)-induced PCSK9 expression in HepG2 cells[2].
Gypenoside LVI (5-20 μM; 24 h) reduces PCSK9 mRNA expression in HepG2 cells[2].
Gypenoside LVI (5-20 μM; 24 h) does not affect SREBP-2 protein expression in HepG2 cells[2].
Gypenoside LVI (5-20 μM; 24 h) does not affect the expression of SREBP-2 or LDLR mRNA in HepG2 cells[2].
Gypenoside LVI (5-20 μM; 24 h) protects LDLR from lysosomal degradation in HepG2 cells via a post-translational pathway[2].
Gypenoside LVI (5-20 μM; 24 h) increases the abundance of LDLR in HepG2 cells[2].
Gypenoside LVI (5-20 μM; 20 h) promotes LDL uptake in HepG2 cells[2].
Gypenoside LVI (5-20 μM; 24 h) increases cell surface LDLR levels in HepG2 cells[2].
Gypenoside LVI (10-50 μM; 3 h) inhibits LPS-induced NO release in BV-2 microglial cells at concentrations of 20 μM and above[3].
Gypenoside LVI (Gyp-LVI) (10-50 μM; 3 h) exerts anti-inflammatory and neuroprotective effects in LPS-induced BV-2 cells by regulating apoptosis-related proteins and downregulating key inflammatory factors[3].
Gypenoside LVI (10-50 μM; 3 h) inhibits LPS-induced activation of the NLRP3 inflammasome signaling pathway in BV-2 microglia[3].
Gypenoside LVI (10-50 μM; 3 h) regulates LPS-induced M1/M2 phenotypic polarization in BV-2 microglia by inhibiting M1 markers (iNOS, CD86) and promoting M2 markers (Arg-1)[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:RAW264.7 murine macrophages
-
Concentration:25, 50, 100 μg/mL
-
Incubation Time:24 h
-
Result:Significantly and dose-dependently promoted ABCG1 gene expression.
Increased SRB1 gene expression.
Up-regulated LXRα gene expression to 0.984 at 25 μg/mL and increased by about 2-fold (1.172) at 100 μg/mL compared to ox-LDL-treated cells (0.633).
-
Cell Line:RAW264.7 murine macrophages
-
Concentration:25, 50, 100 μg/mL
-
Incubation Time:24 h
-
Result:Displayed stimulatory effect on ABCG1 protein expression at 25 μg/mL.
Significantly up-regulated SRB1 protein expression in a dose-dependent manner.
Significantly elevated LXRα protein expression to 0.213, 0.201 and 0.334 at 25, 50 and 100 μg/mL, respectively.\nDramatically suppressed phosphorylation of ERK and JNK.
-
Cell Line:RAW264.7 murine macrophages
-
Concentration:25, 50, 100 μg/mL
-
Incubation Time:24 h
-
Result:Markedly decreased ox-LDL-induced production of IL-6 and IL-1β.
Accumulation of TNF-α was not reduced but instead slightly increased at 25 μg/mL and 50 μg/mL.
Inhibition ratio on IL-1β reached 74.4% at 100 μg/mL.
Attenuated about 11.21%, 22.2% and 55.81% of ox-LDL-induced accumulation of IL-6 at 25, 50 and 100 μg/mL, respectively.
-
Cell Line:HepG2
-
Concentration:20, 40, 60, 80, 100 μM
-
Incubation Time:24 h
-
Result:Inhibited the viability of HepG2 cells.
-
Cell Line:HepG2
-
Concentration:5, 10, 20 μM
-
Incubation Time:24 h
-
Result:Significantly decreased the levels of secreted PCSK9 in a dose-dependent manner.
-
Cell Line:HepG2
-
Concentration:5, 20 μM
-
Incubation Time:24 h
-
Result:Evidently reduced the expression of PCSK9 in total cell lysate compared to the control group.\nSignificantly enhanced LDLR protein levels compared with vehicle-treated cells.\nFailed to alter SREBP-2 protein expression.\nFurther inhibited degradation of LDLR compared with BA1 alone.\nMarkedly decreased the PCSK9 upregulation induced by 1 μM simvastatin.
-
Cell Line:HepG2
-
Concentration:5, 20 μM
-
Incubation Time:24 h
-
Result:Remarkably declined the mRNA level of PCSK9.\nFailed to alter SREBP-2 mRNA expression and exhibited no influence on the mRNA expression of LDLR.
-
Cell Line:HepG2
-
Concentration:5, 20 μM
-
Incubation Time:24 h
-
Result:Increased fluorescence intensity of LDLR on the membrane.
-
Cell Line:LPS-induced BV-2 microglial cells
-
Concentration:10, 20, 50 μM
-
Incubation Time:3 h
-
Result:Exhibited a significant inhibitory effect on NO release at concentrations of 20 μM and above.
-
Cell Line:LPS-induced BV-2 microglial cells
-
Concentration:10, 20, 50 μM
-
Incubation Time:3 h
-
Result:LVI-H (50 μM) significantly reversed the upregulation of Bax and antagonized the downregulation of Bcl-2.
LVI-H (50 μM) significantly suppressed the LPS-induced upregulation of TNF-α, IL-6, and iNOS mRNA.
All tested concentrations significantly downregulated the transcription levels of iNOS and IL-1β.
Western blot confirmed that LPS-induced high expression of IL-1β was significantly inhibited by Gyp-LVI at all concentrations.
-
Cell Line:LPS-induced BV-2 microglial cells
-
Concentration:10, 20, 50 μM
-
Incubation Time:3 h
-
Result:LVI-L (10 μM) and LVI-M (20 μM) markedly inhibited the increased fluorescence intensity of iNOS.
All treatment groups significantly downregulated CD86 expression.
Western blot confirmed that LVI-H (50 μM) significantly reduced CD86 protein levels.
All concentrations of Gyp-LVI significantly upregulated Arg-1 expression.\nLVI-M (20 μM) and LVI-H (50 μM) markedly suppressed the intracellular fluorescence signal of NLRP3.
All concentrations of Gyp-LVI significantly antagonized the upregulation of NLRP3 mRNA expression.
All concentrations of Gyp-LVI significantly downregulated the protein expression of both NLRP3 and Caspase-1.
Only LVI-M (20 μM) showed a statistically significant inhibitory effect on ASC.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57/BL6J (female, 7 months old, chronic unpredictable mild stress (CUMS) model)[3]
-
Dosage:10, 20, 40 mg/kg
-
Administration:i.g.; daily; 10 days
-
Result:Reversed CUMS-induced decrease in total movement distance at 10 and 20 mg/kg in the open field test.
Increased central zone exploration distance at 10 and 20 mg/kg.
Increased licking time at all doses in the sucrose splash test, with a dose-dependent trend.
Shortened immobility time at all doses in the tail suspension test.
Alleviated CUMS-induced body weight abnormality at 10 mg/kg at the end of the fourth week.
Reversed slow weight gain at 10 mg/kg by the fifth week.
Increased rate of body weight change at 10 mg/kg.
Downregulated iNOS and CD86 and upregulated Arg-1 expression in the hippocampus at 20 mg/kg.
Regulated iNOS, CD86, and Arg-1 in the PFC at 20 mg/kg.
Improved various morphological parameters of microglia in the PFC region at 40 mg/kg.
Downregulated NLRP3, Caspase-1, and ASC protein expression in the PFC at 20 mg/kg.
Reversed all measured oxidative stress indices in serum at 20 mg/kg.
Improved most oxidative stress indices in PFC tissue at 20 mg/kg.
Chemical Information
-
CAS. Nr. 105214-48-0
-
Molecular Weight 1095.28
-
Formel C53H90O23
-
SMILES
C[C@]12[C@@]([C@]3(C)[C@@](CC1)(C(C)(C)[C@@H](O[C@H]4[C@H](O[C@@H]5O[C@H](CO)[C@@H](O)[C@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@@H](CO)O4)[C@H](O)C3)[H])(C[C@@H](O)[C@]6([C@@]2(C)CC[C@@]6([C@@](O[C@@H]7O[C@H](CO[C@H]8[C@H](O)[C@@H](O)[C@H](O)CO8)[C@@H](O)[C@H](O)[C@H]7O)(CCC=C(C)C)C)[H])[H])[H]
-
Structure Classification
-
Initial Source
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Protokoll
-
Kinase activity and phosphorylation assays
Kinase activity assays measure the ability of kinases to transfer phosphate groups from ATP to specific substrates, while phosphorylation assays detect the presence and levels of phosphorylated proteins. Common methods include radiolabeled ATP incorporation (e. g. ,), ADP release detection via bioluminescence (e. g. ,[3]), enzyme-linked immunosorbent assays (ELISA) for phospho-specific epitopes (e. g. ,[6]), and microtiter-based formats for high-throughput screening (e. g. ,[8]). The ADP-Glo assay quantifies kinase activity by measuring ADP produced during phosphorylation using a luciferase-based system. Radiometric assays involve autoradiography or scintillation counting after incorporation of 32P-labeled ATP into substrate proteins. ELISA-based approaches rely on phospho-specific antibodies to detect activated kinases in cell lysates or purified samples.
-
Western Blot
Western blotting (WB) is a commonly used experimental method in molecular biology, biochemistry, and immunogenetics for identifying and quantifying target proteins. It combines gel electrophoresis with immunoassay, enabling researchers to analyze protein expression, post-translational modifications, and molecular weight.
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
3T3-L1 preadipocyte-to-adipocyte differentiation
3T3-L1 preadipocytes are induced to differentiate after growth arrest using adipogenic media containing insulin, dexamethasone, and IBMX; differentiation is assessed by lipid-droplet accumulation, triglyceride increase, Oil Red O staining, and adipocyte-marker induction such as PPARγ and C/EBPα.
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
Research Protocol for Cardiovascular Diseases
Cardiovascular disease can be modeled as maladaptive cardiac remodeling, where ischemic injury or pressure overload activates inflammatory signaling, fibroblast activation, extracellular-matrix deposition, cardiomyocyte hypertrophy, vascular remodeling, and progressive ventricular dysfunction. The TGF-β/SMAD axis is a central profibrotic pathway after myocardial injury and pressure overload, while innate immune and cytokine pathways regulate leukocyte recruitment, scar formation, and adverse remodeling. Key unresolved questions include which inflammatory signals are reparative versus harmful, when fibrosis is protective versus maladaptive, and whether pathway inhibition improves function without weakening necessary infarct healing or compensatory remodeling.
-
Protocol for Kinase activity and phosphorylation assays
Kinase activity assays measure transfer of phosphate from ATP to a protein or peptide substrate, generating phosphorylated substrate, ADP, or incorporated radiolabeled phosphate as the readout; phosphorylation assays measure site-specific phosphorylation in cells or tissues as a proxy for kinase-pathway activation, inhibition, or substrate regulation. Phosphorylation can be detected by phospho-specific Western blot, immunoprecipitation kinase assay, phospho-immunofluorescence, phospho-flow cytometry, luminescent ADP detection, radiolabeled ATP incorporation, or reporter-based pathway assays, and these readouts can be applied to cancer cells, primary neurons, mouse tumors, organoids, inflammatory macrophages, ferroptosis studies, and mitophagy studies when the kinase target is biologically relevant.
-
Research Protocol for Neurological Diseases
PINK1/Parkin-mediated mitophagy pathway is a mitochondrial quality-control signaling axis in which mitochondrial depolarization stabilizes PINK1 on damaged mitochondria, activates Parkin recruitment and E3 ubiquitin ligase activity, promotes ubiquitination of outer mitochondrial membrane proteins, recruits selective autophagy adaptors, and drives lysosomal degradation of damaged mitochondria. In neurological disease research, this pathway is experimentally important because neurons, especially dopaminergic neurons, are highly dependent on mitochondrial integrity, and defective mitochondrial turnover can lead to mitochondrial dysfunction, oxidative stress, impaired neuronal survival, α-synuclein accumulation, and neuroinflammatory damage-associated signals. The genetic disease link is strongest in Parkinson’s disease because mutations in PRKN/parkin cause autosomal recessive juvenile parkinsonism, mutations in PINK1 cause hereditary early-onset Parkinson’s disease, and Drosophila studie
-
Pyroptosis Solutions
Pyroptosis is a lytic inflammatory cell-death pathway executed by gasdermin pores, most classically through inflammasome-mediated activation of caspase-1, cleavage of gasdermin D, membrane pore formation, LDH release, and secretion of IL-1β and IL-18. The canonical pathway is commonly modeled by priming cells with an inflammatory signal such as LPS to induce pro-IL-1β and inflammasome components, followed by an activation signal such as ATP or nigericin to activate NLRP3, ASC speck formation, caspase-1 cleavage, GSDMD cleavage, cytokine release, and pyroptotic membrane rupture. The non-canonical pathway is triggered when cytosolic LPS activates mouse caspase-11 or human caspase-4/5, leading to GSDMD cleavage and pyroptosis, and this can secondarily activate NLRP3-dependent IL-1β release. Pyroptosis is linked to inflammatory injury, infection, cancer, liver disease, ocular disease, placental inflammation, and other disease phenotypes, but unresolved questions include which gasdermin fam
-
Lipid Droplets: Oil Red O/Sudan Dye Lipid Staining
Lipid droplets are intracellular organelles with a neutral-lipid core that stores triacylglycerols and sterol esters, and Oil Red O or Sudan dyes detect these hydrophobic lipid deposits by partitioning into retained lipids in fresh or frozen specimens. Oil Red O stains neutral triglycerides and lipids in frozen tissue sections or air-dried cytologic preparations, while Sudan Black B has also been used as a histochemical fat stain for lipid-rich tissue structures.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Reinheit & Dokumentation
Verweise
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)